[A new combination therapy with low-dose FP and daily oral administration of low-dose etoposide--a report of 2 cases].
We report 2 patients with advanced gastric cancer treated with a new combination chemotherapy of low-dose FP and daily oral administration of low-dose etoposide. Patient 1 was an 84-year-old man. He was diagnosed with cancer of the remnant stomach with multiple liver metastases. For eight months, he was treated as an outpatient and his performance status (PS) stayed at stage 1. Patient 2 was a 67-year-old man with lymph node metastasis of the lung. For the first 6 weeks, he was treated under hospitalization and for the following 10 months he was treated as an outpatient. His PS remained in stage 1 and blood CEA value fell from 2,420 ng/ml to 46.9 ng/ml. Upper gastrointestinal series showed a recovery of the extension of his lower gastric body. Both cases were so-called prolonged NC. From the viewpoint of patient QOL, this new combination is a possible candidate for a more effective chemotherapy.
Kato
Tomohiro
T
First Dept. of Internal Medicine, Gifu University School of Medicine.
Yasuda
Ichiro
I
Naito
Tomoo
T
Araki
Hiroshi
H
Miwa
Yoshiyuki
Y
Uematsu
Takahiro
T
Nagaki
Masahito
M
Moriwaki
Hisataka
H
D000230:Adenocarcinoma / Q000188:drug therapy*; D000284:Administration, Oral; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005047:Etoposide / Q000008:administration & dosage; D006801:Humans; D008297:Male; D011788:Quality of Life; D013274:Stomach Neoplasms / Q000188:drug therapy*
D005047:Etoposide; D002945:Cisplatin